Compare TH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | MLTX |
|---|---|---|
| Founded | 1978 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2017 | 2020 |
| Metric | TH | MLTX |
|---|---|---|
| Price | $14.21 | $16.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $16.50 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | N/A |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $38.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $5.95 |
| 52 Week High | $16.12 | $62.75 |
| Indicator | TH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 40.48 |
| Support Level | $7.95 | $15.90 |
| Resistance Level | $15.10 | $16.69 |
| Average True Range (ATR) | 0.56 | 0.87 |
| MACD | -0.27 | -0.22 |
| Stochastic Oscillator | 20.04 | 2.42 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.